RCE
RECCE PHARMACEUTICALS LTD
$0.3700
0.00%
Market cap
$113M
Turnover
$9,998
Last price
$0.3700
Day change
0.00%
Announcements
16
Range, past year
Open 0.440 · Low 0.265 · Now 0.370 · High 0.730
Open RCE in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
RCE momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
43/100
Wyckoff phase
Accumulation12d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+7.2%
1 Month
+27.6%
1 Year
-14.9%
RSI
62
Avg daily range
5.3%
RECCE PHARMACEUTICALS LTD scores 43 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 12 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Volume 2.1× 60-day avg
- RSI in healthy zone (62)
- Early discovery signal (70)
Points to watch
- 60d drawdown -30.3%
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
RCE announcements
Recent price-sensitive releases.
- 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-22 License and Commercialisation Agreement in AUS/NZ for R327G Progress Report
- 2026-10-20 Independent Review of Indonesian Phase 3 R327G Trial Data Progress Report
- 2026-10-16 Amendments to Debt Facility with Avenue Capital Group Debt Facility
- 2026-08-31 Appendix 4E and FY26 Annual Report Corporate Governance | Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-19 HREC Approves Comparator Study for Pivotal Phase 3 DFI Progress Report
- 2026-07-21 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.